Decreased levels of CCR3 in CD4+ lymphocytes of rheumatoid arthritis patients

Clinical and Experimental Rheumatology

Volumn 28, Issue 4, 2010, Pages 462-467

  Aloush, V ^a   George, J ^a   Elkayam, O ^a   Wigler, I ^a   Oren, S ^a   Entin Meer, M ^a   Maysel Auslender, S ^a   Ablin, J N ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

CCR3 receptors; Eotaxin 2; Rantes; Rheumatoid arthritis

Indexed keywords

CCL24 PROTEIN, HUMAN; CCR3 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR3; EOTAXIN 2; RANTES; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; DRUG ANTAGONISM; DRUG POTENTIATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL24; CHEMOKINE CCL5; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR3; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952067031     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. FIRESTEIN GS Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. AREND WP Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheum 2001; 45: 101-6.
3. SZEKANECZ Z, SZUCS G, SZANTO S, KOCH AE Chemokines in rheumatic diseases. Curr Drug Targets 2006; 7: 91-102.
4. PATEL DD, ZACHARIAH JP, WHICHARD LP CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001; 98: 39-45.
5. SZEKANECZ Z, KIM J, KOCH AE Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol 2003; 15: 15-21.
6. RUTH JH, ROTTMAN JB, KATSCHKE KJ JR et al. Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001; 44: 2750-60.
7. KATSCHKE KJ JR, ROTTMAN JB, RUTH JH et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid, and synovial tissue monocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1022-32.
8. GRIFFITHS-JOHNSON DA, COLLINS PD, ROSSI AG, JOSE PJ, WILLIAMS TJ The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Commun 1993; 197: 1167-72.
9. JOSE PJ, ADCOCK IM, GRIFFITHS-JOHNSON DA et al. Eotaxin: cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. Biochem Biophys Res Commun 1994; 205: 788-94.
10. ROTHENBERG ME, LUSTER AD, LEDER P Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc Natl Acad Sci USA 1995; 92: 8960-4.
11. PONATH PD, QIN S, RINGLER DJ et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97: 604-12.
12. MACLEAN JA, OWNBEY R, LUSTER AD T cell-dependent regulation of eotaxin in antigen-induced pulmonary eosinophila. J Exp Med 1996; 184: 1461-9.
13. HEIN H, SCHLUTER C, KULKE R, CHRISTOPHERS E, SCHRODER JM, BARTELS J Genomic organization, sequence, and transcriptional regulation of the human eotaxin gene. Biochem Biophys Res Commun 1997; 237: 537-42.
14. TERAN LM, MOCHIZUKI M, BARTELS J et al. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999; 20: 777-86.
15. STELLATO C, MATSUKURA S, FAL A et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J Immunol 1999; 163: 5624-32.
16. MATSUKURA S, STELLATO C, PLITT JR et al. Activation of eotaxin gene transcription by NF-kappa B and STAT6 in human airway epithelial cells. J Immunol 1999; 163: 6876-83.
17. PATEL VP, KREIDER BL, LI Y et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med 1997; 185: 1163-72.
18. WHITE JR, IMBURGIA C, DUL E et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997; 62: 667-75.
19. FORSSMANN U, UGUCCIONI M, LOETSCHER P et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997; 185: 2171-6.
20. KITAURA M, SUZUKI N, IMAI T et al. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999; 274: 27975-80.
21. SHINKAI A, YOSHISUE H, KOIKE M et al. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J Immunol 1999; 163: 1602-10.
22. KITAURA M, SUZUKI N, IMAI T et al. Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3. J Biol Chem 1999; 274: 27975-80.
23. YING S, MENG Q, ZEIBECOGLOU K et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J Immunol 1999; 163: 6321-9.
24. WHITE JR, IMBURGIA C, DUL E et al. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils. J Leukoc Biol 1997; 62: 667-75.
25. HUMBLES AA, CONROY DM, MARLEAU S et al. Kinetics of eotaxin generation and its relationship to eosinophil accumulation in allergic airways disease: analysis in a guinea pig model in vivo. J Exp Med 1997; 186: 601-12.
26. ALAM R Chemokines in allergic inflammation. J Allergy Clin Immunol 1997; 99: 273-7.
27. CORRIGAN CJ Eotaxin and asthma: some answers, more questions. Clin Exp Immunol 1999; 116: 1-3.
28. DE LUCCA GV Recent developments in CCR3 antagonists. Curr Opin Drug Discov Devel 2006; 9: 516-24.
29. ARNETT FC, EDWORTHY SM, BLOCH DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
30. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, VAN DE PUTTE LB, VAN RIEL PL Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
31. TACHIMOTO H, BURDICK MM, HUDSON SA, KIKUCHI M, KONSTANTOPOULOS K, BOCHNER BS CCR3-active chemokines promote rapid detachment of eosinophils from VCAM-1 in vitro. J Immunol 2000; 165: 2748-54.
32. TACHIMOTO H, KIKUCHI M, HUDSON SA, BICKEL CA, HAMILTON RG, BOCHNER BS Eotaxin-2 alters eosinophil integrin function via mitogen-activated protein kinases. Am J Respir Cell Mol Biol 2002; 26: 645-9.
33. HEATH H, QIN S, RAO P et al. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997; 99: 178-84.
34. SHAHRARA S, PROUDFOOT AE, WOODS JM et al. Amelioration of rat adjuvant-induced arthritis by Met-RANTES. Arthritis Rheum 2005; 52: 1907-19.
35. HAAS CS, MARTINEZ RJ, ATTIA N, HAINES GK, III, CAMPBELL PL, KOCH AE Chemokine receptor expression in rat adjuvant-induced arthritis. Arthritis Rheum 2005; 52: 3718-30.
36. RATHANASWAMI P, HACHICHA M, SADICK M, SCHALL TJ, MCCOLL SR Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines. J Biol Chem 1993; 268: 5834-9.
37. ROBINSON E, KEYSTONE EC, SCHALL TJ, GILLETT N, FISH EN Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 1995; 101: 398-407.
38. IWAMOTO T, OKAMOTO H, IIKUNI N et al. Monocyte chemoattractant protein-4 (MCP-4)/CCL13 is highly expressed in cartilage from patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 421-4.
39. KITAURA M, NAKAJIMA T, IMAI T et al. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996; 271: 7725-30.
40. PONATH PD, QIN S, RINGLER DJ et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest 1996; 97: 604-12.
41. BOCCHINO V, BERTORELLI G, BERTRAND CP et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 2002; 57: 17-22.
42. HUEBER W, TOMOOKA BH, ZHAO X et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712-9.
43. DE JAGER W, HOPPENREIJS EP, WULFFRAAT NM, WEDDERBURN LR, KUIS W, PRAKKEN BJ Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007; 66: 589-98.
44. BEN S, LI X, XU F et al. Treatment with anti-CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34 progenitor cells in an allergic mouse model. Allergy 2008; 63: 1164-76.
45. NISSINEN R, LEIRISALO-REPO M, PELTOMAA R, PALOSUO T, VAARALA O Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 681-7.
46. STELLATO C, BRUMMET ME, PLITT JR et al. Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells. J Immunol 2001; 166: 1457-61.
47. COURY F, FERRARO-PEYRET C, LE CAM S et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by antitumour necrosis factor-alpha therapy. Clin Exp Rheumatol 2008; 26: 234-9.
48. WIJNGAARDEN S, VAN DE WINKEL JG, BIJLSMA JW, LAFEBER FP, VAN ROON JA Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fcgamma receptor I on monocytes. Clin Exp Rheumatol 2008; 26: 89-95.